Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

NCT07110246 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

96

Enrollment

OTHER

Sponsor class

Conditions

BRAF V600 Mutation
Low-grade Glioma
Low Grade Glioma of Brain
Recurrent Low Grade Glioma

Interventions

DRUG: Dabrafenib
DRUG: Trametinib
PROCEDURE: Magnetic Resonance Imaging (MRI)
PROCEDURE: Specimen Collection
PROCEDURE: Optional Lumbar puncture

Sponsor

University of California, San Francisco

Collaborators

[object Object]